Annual Report

The report presents Chugai’s 2015 consolidated results, with revenues of 498.8 billion yen and 8.2% growth. It highlights strong sales in oncology and bone and joint diseases, alongside the U.S. approval of Alecensa and breakthrough-therapy designations for innovative drug candidates. It also describes environmental and safety initiatives, including a 13% reduction in energy consumption per employee since 2010 for the Chugai Group in Japan.